7.77
-0.11
(-1.40%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 7.72 - 8.04 |
| 52 week | 4.41 - 8.50 |
| Open | 7.84 |
| Vol / Avg. | 868,733.00/817,858.00 |
| Mkt cap | 371.97M |
| P/E | - |
| Div/yield | - |
| EPS | -1.56 |
| Shares | 47.87M |
| Beta | - |
| Inst. own | 68% |
Events
Apr 5, 2013
TRIUS THERAPEUTICS INC at BioCentury Publications Future Leaders in the Biotech Industry Conference -
Mar 25, 2013
TRIUS THERAPEUTICS INC Call To Discuss Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections
Mar 12, 2013
TRIUS THERAPEUTICS INC at EBD BIO-Europe Spring
Feb 26, 2013
TRIUS THERAPEUTICS INC at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1000.58% | -198.37% |
| Operating margin | -887.20% | -210.53% |
| EBITD margin | - | -208.10% |
| Return on average assets | -83.97% | -75.21% |
| Return on average equity | -107.41% | -101.10% |
| Employees | 90 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 101, 6310 Nancy Ridge Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-4520370 (Phone)
+1-858-6779975 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-4520370 (Phone)
+1-858-6779975 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Trius Therapeutics, Inc. operates as a biopharmaceutical research company. It has a cooperative research and development agreement with Lawrence Livermore National Security LLC for the research and development of gram-negative biodefense pathogens; and a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and sell Torezolid Phosphate outside of Korea.
Officers and directors
| David S. Kabakoff Ph.D. | Independent Chairman of the Board | |
| Jeffrey Stein Ph.D. | President, Chief Executive Officer, Director | |
| John P. Schmid | Chief Financial Officer | |
| John Finn Ph.D. | Chief Scientific Officer | |
| Michael Morneau | Vice President - Finance, Chief Accounting Officer | |
| Kenneth Bartizal Ph.D. | Chief Development Officer | |
| Philippe G. Prokocimer M.D. | Chief Medical Officer | |
| J. Craig Thompson | Chief Commercial Officer | |
| Seth H. Z. Fischer | Director | |
| Brian G. Atwood | Independent Director |